Analysis of HIV-1 gag protein interactions via biotin ligase tagging

Journal of Virology

Volumn 89, Issue 7, 2015, Pages 3988-4001

  Ritchie, Christopher ^a   Cylinder, Isabel ^a   Platt, Emily J ^a   Barklis, Eric ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; BIOTIN; BIOTIN LIGASE; CYTOSKELETON PROTEIN; GAG PROTEIN; LIGASE; MATRIX PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; BIRA PROTEIN, E COLI; ESCHERICHIA COLI PROTEIN; REPRESSOR PROTEIN;

ARTICLE; BIOTINYLATION; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; VIRION; GENETICS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; PROCEDURES; REPORTER GENE; STAINING;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1;

BIOTIN; CARBON-NITROGEN LIGASES; ESCHERICHIA COLI PROTEINS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, REPORTER; HIV-1; HOST-PATHOGEN INTERACTIONS; PROTEIN INTERACTION MAPPING; REPRESSOR PROTEINS; STAINING AND LABELING;

EID: 84924787747     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03584-14     Document Type: Article

References (95)

1. Brügger B, Glass B, Haberkant P, Leibrecht I, Wieland F, Krausslich H-G. 2006. The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci USA 103:2641-2646. http://dx.doi.org/10.1073/pnas.0511136103.
2. Bryant M, Ratner L. 1990. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 87:523-527. http://dx.doi.org/10.1073/pnas.87.2.523.
3. Chukkapalli V, Hogue IB, Boyko V, Hu WS, Ono A. 2008. Interaction between HIV-1 Gag matrix domain and phosphatidylinositol-(4,5)-bisphosphate is essential for efficient Gag-membrane binding. J Virol 82: 2405-2417. http://dx.doi.org/10.1128/JVI.01614-07.
4. Chukkapalli V, Oh SJ, Ono A. 2010. Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane binding through the highly basic region of the matrix domain. Proc Natl Acad Sci USA 107: 1600-1605. http://dx.doi.org/10.1073/pnas.0908661107.
5. Graham D, Chertova E, Hilburn J, Arthur L, Hildreth J. 2003. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol 77: 8237-8248. http://dx.doi.org/10.1128/JVI.77.15.8237-8248.2003.
6. Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO. 2004. Phosphatidylinositol(4,5)bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci USA 101:14889-14894. http://dx.doi.org/10.1073/pnas.0405596101.
7. Ono A, Freed EO. 2001. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 98:13925-13930. http://dx.doi.org/10.1073/pnas.241320298.
8. Ono A, Waheed A, Freed EO. 2007. Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology 360:27-35. http://dx.doi.org/10.1016/j.virol.2006.10.011.
9. Alfadhli A, Still A, Barklis E. 2009. Analysis of human immunodeficiency virus type 1 matrix binding to membranes and nucleic acids. J Virol 83: 12196-12203. http://dx.doi.org/10.1128/JVI.01197-09.
10. Alfadhli A, McNett H, Eccles J, Tsagli S, Noviello C, Sloan R, Lopez C, Peyton D, Barklis E. 2013. Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site. J Biol Chem 288:666-676. http://dx.doi.org/10.1074/jbc.M112.399865.
11. Alfadhli A, McNett H, Tsagli S, Bachinger HP, Peyton DH, Barklis E. 2011. HIV-1 matrix protein binding to RNA. J Mol Biol 410:653-666. http://dx.doi.org/10.1016/j.jmb.2011.04.063.
12. Saad JS, Miller J, Tai J, Kim A, Ghanam RH, Summers MF. 2006. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci USA 103:11364-11369. http://dx.doi.org/10.1073/pnas.0602818103.
13. Jones CP, Datta SA, Rein A, Rouzina I, Musier-Forsyth K. 2011. Matrix domain modulates HIV-1 Gag's nucleic acid chaperone activity via inositol phosphate binding. J Virol 85:1594-1603. http://dx.doi.org/10.1128/JVI.01809-10.
14. Kutluay S, Zang T, Blanco-Melo D, Powell C, Jannain D, Errando M, Bieniasz P. 2014. Global changes in the RNA binding specificity of HIV-1 Gag regulate virion genesis. Cell 159:1096-1109. http://dx.doi.org/10.1016/j.cell.2014.09.057.
15. Aldovini A, Young RA. 1990. Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol 64:1920-1926.
16. Berkowitz R, Fisher J, Goff SP. 1996. RNA packaging. Curr Top Microbiol Immunol 214:177-218.
17. Buckman J, Bosche W, Gorelick R. 2003. Human immunodeficiency virus type 1 nucleocapsid Zn2 fingers are required for efficient reverse transcription, initial integration processes, and protection of newly synthesized viral DNA. J Virol 77:1469-1480. http://dx.doi.org/10.1128/JVI.77.2.1469-1480.2003.
18. Gorelick R, Chabot D, Rein A, Henderson L, Arthur LO. 1993. The two zinc fingers in the human immunodeficiency virus type 1 nucleocapsid protein are not functionally equivalent. J Virol 67:4027-4036.
19. Kaye J, Lever A. 1996. Trans-acting proteins involved in RNA encapsidation and viral assembly in human immunodeficiency virus type 1. J Virol 70:880-886.
20. Swanstrom R, Wills JW. 1997. Synthesis, assembly, and processing of viral proteins, p 263-334. In Coffin J, Hughes S, Varmus H (ed), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
21. Garrus J, von Schwedler U, Pornillos O, Morham S, Zavitz K, Wang H, Wettstein D, Stray K, Côté M, Rich R, Myszka D, Sundquist W. 2001. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107:55-65. http://dx.doi.org/10.1016/S0092-8674(01)00506-2.
22. Milev M, Ravichandran M, Khan M, Schriemer D, Mouland A. 2012. Characterization of staufen1 ribonucleoproteins by mass spectrometry and biochemical analyses reveal the presence of diverse host proteins associated with human immunodeficiency virus type 1. Front Microbiol 3:367.
23. Strack B, Calistri A, Craig S, Popova E, Gottlinger H. 2003. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114:689-699. http://dx.doi.org/10.1016/S0092-8674(03)00653-6.
24. VerPlank L, Bouamr F, LaGrassa T, Agresta B, Kikonyogo A, Leis J, Carter C. 2001. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc Natl Acad SciUSA 98:7724-7729. http://dx.doi.org/10.1073/pnas.131059198.
25. von Schwedler U, Stuchell M, Müller B, Ward D, Chung H, Morita E, Wang H, Davis T, He G, Cimbora D, Scott A, Kräusslich H-G, Kaplan J, Morham S, Sundquist W. 2003. The protein network of HIV budding. Cell 114:701-713. http://dx.doi.org/10.1016/S0092-8674(03)00714-1.
26. Watanabe S, Chen M-H, Khan M, Ehrlich L, Kemal KS, Weiser B, Shi B, Chen C, Powell M, Anastos K, Burger H, Carter CA. 2013. The S40 residue in HIV-1 Gag p6 impacts local and distal budding determinants, revealing additional late domain activities. Retrovirology 10:143. http://dx.doi.org/10.1186/1742-4690-10-143.
27. Freed EO, Martin MA. 1996. Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 70:341-351.
28. Murakami T, Freed EO. 2000. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and-helix 2 of the gp41 cytoplasmic tail. J Virol 74:3548-3554. http://dx.doi.org/10.1128/JVI.74.8.3548-3554.2000.
29. Tedbury PR, Ablan SD, Freed EO. 2013. Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure. PLoS Pathog 9:e1003739. http://dx.doi.org/10.1371/journal.ppat.1003739.
30. Wang C, Zhang Y, McDermott J, Barklis E. 1993. Conditional infectivity of a human immunodeficiency virus matrix domain deletion mutant. J Virol 67:7067-7076.
31. Yu X, Yuan X, Matsuda Z, Lee TH, Essex M. 1992. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 66:4966-4971.
32. Checkley MA, Luttge B, Freed EO. 2011. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410:582-608. http://dx.doi.org/10.1016/j.jmb.2011.04.042.
33. Burns JC, Friedmann T, Driever W, Burrascano M, Yee J-K. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90:8033-8037. http://dx.doi.org/10.1073/pnas.90.17.8033.
34. Jorgenson RL, Vogt VM, Johnson MC. 2009. Foreign glycoproteins can be actively recruited to virus assembly sites during pseudotyping. J Virol 83:4060-4067. http://dx.doi.org/10.1128/JVI.02425-08.
35. Ott D. 2008. Cellular proteins detected in HIV-1. Rev Med Virol 18:159-175. http://ncifrederick.cancer.gov/research/avp/protein_db.asp.http://dx.doi.org/10.1002/rmv.570.
36. Santos S, Obukhov Y, Nekhai S, Bukrinsky M, Iordanskiy S. 2012. Virus-producing cells determine the host protein profiles of HIV-1 virion cores. Retrovirology 9:65. http://dx.doi.org/10.1186/1742-4690-9-65.
37. Berthoux L, Pechoux C, Ottmann M, Morel G, Darlix JL. 1997. Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J Virol 71:6973-6981.
38. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365:666-669. http://dx.doi.org/10.1038/365666a0.
39. Lamorte L, Titolo S, Lemke C, Goudreau N, Mercier J, Wardrop E, Shah V, von Schwedler U, Langelier C, Banik S, Aiken C, Sundquist W, Mason S. 2013. Discovery of novel small-molecule HIV-1 replication inhibitors that stabilize capsid complexes. Antimicrob Agents Chemother 57:4622-4631. http://dx.doi.org/10.1128/AAC.00985-13.
40. Lee K, Ambrose Z, Martin T, Oztop I, Mulky A, Julias J, Vandegraaff N, Baumann J, Wang R, Yuen W, Takemura T, Shelton K, Taniuchi I, Li Y, Sodroski J, Littman D, Coffin J, Hughes S, Unutmaz D, Engelman A, KewalRamani V. 2010. Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe 7:221-233. http://dx.doi.org/10.1016/j.chom.2010.02.007.
41. Monette A, Panté N, Mouland A. 2011. HIV-1 remodels the nuclear pore complex. J Cell Biol 193:619-631. http://dx.doi.org/10.1083/jcb.201008064.
42. Price A, Jacques D, McEwan W, Fletcher A, Essig S, Chin J, Halambage U, Aiken C, James L. 2014. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog 10:e1004459. http://dx.doi.org/10.1371/journal.ppat.1004459.
43. Goujon C, Moncorgé O, Bauby H, Doyle T, Ward C, Schaller T, Hué S, Barclay W, Schulz R, Malim M. 2013. Human MX2 is an interferoninduced post-entry inhibitor of HIV-1 infection. Nature 502:559-562. http://dx.doi.org/10.1038/nature12542.
44. Kane M, Yadav S, Bitzegeio J, Kutluay S, Zang T, Wilson S, Schoggins J, Rice C, Yamashita M, Hatziioannou T, Bieniasz P. 2013. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502:563-566. http://dx.doi.org/10.1038/nature12653.
45. Liu Z, Pan Q, Ding S, Qian J, Xu F, Zhou J, Cen S, Guo F, Liang C. 2013. The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe 14:398-410. http://dx.doi.org/10.1016/j.chom.2013.08.015.
46. Malim M, Bieniasz P. 2012. HIV restriction factors and mechanisms of evasion. Cold Spring Harb Perspect Med 2:a006940. http://dx.doi.org/10.1101/cshperspect.a006940.
47. Ohmine S, Sakuma R, Sakuma T, Thatava T, Takeuchi H, Ikeda Y. 2011. The antiviral spectra of TRIM5 orthologues and human TRIM family proteins against lentiviral production. PLoS One 6:e16121. http://dx.doi.org/10.1371/journal.pone.0016121.
48. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG. 1998. Efficient HIV-1 replication can occur in the absence of the viral matrix protein. EMBO J 17:2699-2708. http://dx.doi.org/10.1093/emboj/17.9.2699.
49. Scholz I, Arvidson B, Huseby D, Barklis E. 2005. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J Virol 79:1470-1479. http://dx.doi.org/10.1128/JVI.79.3.1470-1479.2005.
50. Engeland C, Brown N, Börner K, Schümann M, Krause E, Kaderali L, Müller G, Kräusslich HG. 2014. Proteome analysis of the HIV-1 Gag interactome. Virology 460-461:194-206. http://dx.doi.org/10.1016/j.virol.2014.04.038.
51. Müller B, Daecke J, Fackler O, Dittmar M, Zentgraf H, Kräusslich H-G. 2004. Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 78:10803-10813. http://dx.doi.org/10.1128/JVI.78.19.10803-10813.2004.
52. Scholz I, Still A, Dhenub TC, Coday K, Webb M, Barklis E. 2008. Analysis of human immunodeficiency virus matrix domain replacements. Virology 371:322-335. http://dx.doi.org/10.1016/j.virol.2007.10.010.
53. Kim D, Birendra K, Zhu W, Motamedchaboki K, Doye V, Roux K. 2014. Probing nuclear pore complex architecture with proximitydependent biotinylation. Proc Natl Acad Sci USA 111:E2453-61.
54. Mechold U, Gilbert C, Ogryzko V. 2005. Codon optimization of the BirA enzyme gene leads to higher expression and an improved efficiency of biotinylation of target proteins in mammalian cells. J Biotechnol 116:245-249. http://dx.doi.org/10.1016/j.jbiotec.2004.12.003.
55. Roux K, Kim D, Raida M, Burke B. 2012. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J Cell Biol 196:801-810. http://dx.doi.org/10.1083/jcb.201112098.
56. Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A, Martin M. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
57. Noviello C, López C, Kukull B, McNett H, Still A, Eccles J, Sloan R, Barklis E. 2011. Second-site compensatory mutations of HIV-1 capsid mutations. J Virol 85:4730-4738. http://dx.doi.org/10.1128/JVI.00099-11.
58. Zhang Y, Barklis E. 1997. Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation. J Virol 71: 6765-6776.
59. DuBridge R, Tang P, Hsia H, Leong P, Miller J, Calos M. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7:379-387.
60. López C, Tsagli S, Sloan R, Eccles J, Barklis E. 2013. Second site reversion of a mutation near the amino terminus of the HIV-1 capsid protein. Virology 447:95-103. http://dx.doi.org/10.1016/j.virol.2013.08.023.
61. López C, Sloan R, Cylinder I, Kozak S, Kabat D, Barklis E. 2014. RRE-dependent HIV-1 Env RNA effects on Gag protein expression, assembly and release. Virology 462-463:126-134. http://dx.doi.org/10.1016/j.virol.2014.05.019.
62. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671-675. http://dx.doi.org/10.1038/nmeth.2089.
63. Adler J, Parmryd I. 2010. Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander's overlap coefficient. Cytometry A 77:733-742. http://dx.doi.org/10.1002/cyto.a.20896.
64. Shevchenko A, Tomas H, Havli J, Olsen J, Mann M. 2006. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1:2856-2860. http://dx.doi.org/10.1038/nprot.2006.468.
65. Wilmarth P, Riviere M, David LL. 2009. Techniques for accurate protein identification in shotgun proteomic studies of human, mouse, bovine, and chicken lenses. J Ocul Biol Dis Infor 2:223-234. http://dx.doi.org/10.1007/s12177-009-9042-6.
66. Keller A, Nesvizhskii A, Kolker E, Aebersold R. 2002. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:5383-5392. http://dx.doi.org/10.1021/ac025747h.
67. Bushman F, Malani N, Fernandes J, D'Orso I, Cagney G, Diamond T, Zhou H, Hazuda D, Espeseth A, König R, Bandyopadhyay S, Ideker T, Goff S, Krogan N, Frankel A, Young J, Chanda S. 2009. Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog May 5:e1000437. http://dx.doi.org/10.1371/journal.ppat.1000437.
68. Shoeman RL, Hartig R, Hauses C, Traub P. 2002. Organization of focal adhesion plaques is disrupted by action of die HIV-1 protease. Cell Biol Int 26:529-539. http://dx.doi.org/10.1006/cbir.2002.0895.
69. Ptak R, Fu W, Sanders-Beer B, Dickerson J, Pinney J, Robertson D, Rozanov M, Katz K, Maglott D, Pruitt K, Dieffenbach C. 2008. Cataloguing the HIV-1 human protein interaction network. AIDS Res Hum Retroviruses 24:1497-1502. http://www.ncbi.nlm.nih.gov/genome/viruses/retroviruses/hiv-1/interactions/.http://dx.doi.org/10.1089/aid.2008.0113.
70. Hoque M, Hanauske-Abel H, Palumbo P, Saxena D, Gandolfi DD, Park MH, Pe'ery T, Mathews MB. 2009. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6:90. http://dx.doi.org/10.1186/1742-4690-6-90.
71. Jäger S, Cimermancic P, Gulbahce N, Johnson J, McGovern K, Clarke S, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang G, Roth S, Akiva E, Marlett J, Stephens M, D'Orso I, Fernandes J, Fahey M, Mahon C, O'Donoghue A, Todorovic A, Morris J, Maltby D, Alber T, Cagney G, Bushman F, Young J, Chanda S, Sundquist W, Kortemme T, Hernandez R, Craik C, Burlingame A, Sali A, Frankel A, Krogan N. 2012. Global landscape of HIV-human protein complexes. Nature 481: 365-370.
72. Yeung ML, Houzet L, Venkat S, Yedavalli RK, Jeang K-T. 2009. A genome-wide short hairpin RNA screening of Jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem 284: 19463-19473. http://dx.doi.org/10.1074/jbc.M109.010033.
73. Chable-Bessia C, Meziane O, Latreille D, Triboulet R, Zamborlini A, Wagschal A, Jacquet J-M, Reynes J, Levy Y, Saib A, Bennasser Y, Benkirane M. 2009. Suppression of HIV-1 replication by microRNA effectors. Retrovirology 6:26. http://dx.doi.org/10.1186/1742-4690-6-26.
74. Brass A, Dykxhoorn D, Benita Y, Yan N, Engelman A, Xavier R, Lieberman J, Elledge S. 2008. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319:921-926. http://dx.doi.org/10.1126/science.1152725.
75. Gallo D, Hope T. 2012. Knockdown of MAP4 and DNAL1 produces a post-fusion and pre-nuclear translocation impairment in HIV-1 replication. Virology 422:13-21. http://dx.doi.org/10.1016/j.virol.2011.09.015.
76. König R, Zhou Y, Elleder D, Diamond T, Bonamy G, Irelan J, Chiang C, Tu B, De Jesus P, Lilley C, Seidel S, Opaluch A, Caldwell J, Weitzman M, Kuhen K, Bandyopadhyay S, Ideker T, Orth A, Miraglia L, Bushman F, Young J, Chanda S. 2008. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135:49-60. http://dx.doi.org/10.1016/j.cell.2008.07.032.
77. Cooper J1, Liu L, Woodruff EA, Taylor HE, Goodwin JS, D'Aquila RT, Spearman P, Hildreth JE, Dong X. 2011. Filamin A protein interacts with human immunodeficiency virus type 1 Gag protein and contributes to productive particle assembly. J Biol Chem 286:28498-28510. http://dx.doi.org/10.1074/jbc.M111.239053.
78. Cimarelli A, Luban J. 1999. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol 73:5388-5401.
79. Engeland C, Oberwinkler H, Schümann M, Krause E, Müller G, Kräusslich H-G. 2011. The cellular protein lyric interacts with HIV-1 Gag. J Virol 85:13322-13332. http://dx.doi.org/10.1128/JVI.00174-11.
80. Impens F, Timmerman E, Staes A, Moens K, Ariën K, Verhasselt B, Vandekerckhove J, Gevaert K. 2012. A catalogue of putative HIV-1 protease host cell substrates. Biol Chem 393:915-931. http://dx.doi.org/10.1515/hsz-2012-0168.
81. Ingaramo M, Beckett D. 2012. Selectivity in post-translational biotin addition to five human carboxylases. J Biol Chem 287:1813-1822. http://dx.doi.org/10.1074/jbc.M111.275982.
82. Abu-Elheiga L, Brinkley W, Zhong L, Chirala S, Woldegiorgis G, Wakil S. 2000. The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci USA 97:1444-1449. http://dx.doi.org/10.1073/pnas.97.4.1444.
83. Fäcke M, Janetzko A, Shoeman R, Krausslich H-G. 1993. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol 67:4972-4980.
84. Jolly C, Mitar I, Sattentau Q. 2007. Requirement for an intact T-cell actin and tubulin cytoskeleton for efficient assembly and spread of human immunodeficiency virus type 1. J Virol 81:5547-5560. http://dx.doi.org/10.1128/JVI.01469-06.
85. Zhou H, Xu M, Huang Q, Gates A, Zhang X, Castle J, Stec E, Ferrer M, Strulovici B, Hazuda D, Espeseth A. 2008. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4:495. http://dx.doi.org/10.1016/j.chom.2008.10.004.
86. Morita E, Sandrin V, Chung H, Morham S, Gygi S, Rodesch C, Sundquist W. 2007. Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J 26:4215-4227. http://dx.doi.org/10.1038/sj.emboj.7601850.
87. Benaud C, Gentil BJ, Assard N, Court M, Garin J, Delphin C, Baudier J. 2004. AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. J Cell Biol 164:133-144. http://dx.doi.org/10.1083/jcb.200307098.
88. Rai T, Mosoian A, Resh M. 2010. Annexin 2 is not required for human immunodeficiency virus type 1 particle production but plays a cell typedependent role in regulating infectivity. J Virol 84:9783-9792. http://dx.doi.org/10.1128/JVI.01584-09.
89. van't Wout A, Swain JV, Schindler M, Rao U, Pathmejeyan M, Mullins J, Kirchhoff F. 2005. Nef induces multiple genes involved in cholesterol synthesis and uptake in human immunodeficiency virus type 1-infected T cells. J Virol 79:10053-10058. http://dx.doi.org/10.1128/JVI.79.15.10053-10058.2005.
90. Abrahamyan L, Chatel-Chaix L, Ajamian L, Milev M, Monette A, Clément J, Song R, Lehmann M, DesGroseillers L, Laughrea M, Boccaccio G, Mouland A. 2010. Novel Staufen1 ribonucleoproteins prevent formation of stress granules but favour encapsidation of HIV-1 genomic RNA. J Cell Sci 123:369-383. http://dx.doi.org/10.1242/jcs.055897.
91. Chatel-Chaix L, Clément J, Martel C, Bériault V, Gatignol A, DesGroseillers L, Mouland A. 2004. Identification of Staufen in the human immunodeficiency virus type 1 Gag ribonucleoprotein complex and a role in generating infectious viral particles. Mol Cell Biol 24:2637-2648. http://dx.doi.org/10.1128/MCB.24.7.2637-2648.2004.
92. Chatel-Chaix L, Germain M-A, Motorina A, Bonneil E, Thibault P, Baril M, Lamarre D. 2013. A host YB-1 ribonucleoprotein complex is hijacked by hepatitis C virus for the control of NS3-dependent particle production. J Virol 87:11704-11720. http://dx.doi.org/10.1128/JVI.01474-13.
93. Chen A, Sengupta P, Waki K, Van Engelenburg S, Ochiya T, Ablan S, Freed EO, Lippincott-Schwartz J. 2014. MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production. Proc Natl Acad Sci USA 111:E2676-83. http://dx.doi.org/10.1073/pnas.1408037111.
94. Lorgeoux RP, Guo F, Liang C. 2012. From promoting to inhibiting: diverse roles of helicases in HIV-1 replication. Retrovirology 9:79. http://dx.doi.org/10.1186/1742-4690-9-79.
95. Reed J, Molter B, Geary C, McNevin J, McElrath J, Giri S, Klein K, Lingappa J. 2012. HIV-1 Gag co-opts a cellular complex containing DDX6, a helicase that facilitates capsid assembly. J Cell Biol 198:439-456. http://dx.doi.org/10.1083/jcb.201111012.